Education
About Us
Working with TipRanks
Follow Us
IRLAB Therapeutics AB Class A (DE:6IRA)
:6IRA
RESEARCH TOOLSreports
6IRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.32 - €1.46
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€17.68M
Enterprise Value€1.74B
Total Cash (Recent Filing)€88.61M
Total Debt (Recent Filing)kr66.46M
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding90,630,104
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.83
Price to Sales (P/S)0.00
P/FCF Ratio-13.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
IRLAB Therapeutics AB Class A News
PremiumCompany Announcements
IRLAB Therapeutics Secures Funding for Parkinson’s Drug Development
PremiumCompany Announcements
IRLAB Therapeutics AB 2025 Annual General Meeting Resolutions
PremiumCompany Announcements
IRLAB Therapeutics to Present at Aktiedagarna Event in Stockholm
PremiumCompany Announcements
IRLAB Therapeutics Reports Positive Phase I Results for IRL757
PremiumCompany Announcements
IRLAB Therapeutics to Present at BioStock Global Forum 2025
PremiumCompany Announcements
IRLAB Secures Extended US Patent for MesdopetamOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
6IRA FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.32 and its highest was €1.46 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €17.68M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is Aug 27, 2025 which is in 56 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on May 07, 2025. The company reported -€0.059 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.059.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 90,630,104 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of -€0.059 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 9.524%.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
Technical Analysis
Oncopeptides AB
―
Xbrane Biopharma AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―